RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis
USA - NASDAQ:RIGL - US7665597024 - Common Stock
41.94 USD
-4.28 (-9.26%)
RIGL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. RIGL has an excellent financial health rating, but there are some minor concerns on its profitability. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, RIGL could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
In the past 5 years RIGL reported 4 times negative net income.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
RIGL has a Return On Equity of 96.34%. This is amongst the best in the industry. RIGL outperforms 99.25% of its industry peers.
With an excellent Return On Invested Capital value of 63.44%, RIGL belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 40.17%, RIGL belongs to the best of the industry, outperforming 97.19% of the companies in the same industry.
RIGL's Operating Margin of 42.17% is amongst the best of the industry. RIGL outperforms 98.87% of its industry peers.
Looking at the Gross Margin, with a value of 93.10%, RIGL belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
RIGL's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RIGL has more shares outstanding
Compared to 5 years ago, RIGL has less shares outstanding
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.09, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
RIGL has a better Altman-Z score (-0.09) than 61.54% of its industry peers.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.88, RIGL belongs to the best of the industry, outperforming 94.00% of the companies in the same industry.
RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 68.29% of the companies in the same industry are doing better.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.09 |
ROIC/WACC7.12
WACC8.91%
2.3 Liquidity
RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL has a Current ratio of 2.28. This is in the lower half of the industry: RIGL underperforms 72.05% of its industry peers.
RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.14, RIGL is not doing good in the industry: 71.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 79.13%.
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 29.86% on average per year.
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 14.40% on average per year.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.80, the valuation of RIGL can be described as very cheap.
97.94% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.46, RIGL is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.89, the valuation of RIGL can be described as reasonable.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 97.19% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.39, RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.8 | ||
| Fwd PE | 10.89 |
4.2 Price Multiples
98.50% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
RIGL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RIGL is cheaper than 97.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.04 | ||
| EV/EBITDA | 5.46 |
4.3 Compensation for Growth
RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 61.96% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RIGL (11/19/2025, 2:57:35 PM)
41.94
-4.28 (-9.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change15.25%
Ins Owners2.58%
Ins Owner Change1.84%
Market Cap752.40M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts76.67
Price Target39.1 (-6.77%)
Short Float %19.68%
Short Ratio5.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)13.61%
EPS NQ rev (1m)26.13%
EPS NQ rev (3m)136.63%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)1.72%
Revenue NQ rev (3m)7.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.8 | ||
| Fwd PE | 10.89 | ||
| P/S | 2.67 | ||
| P/FCF | 11.04 | ||
| P/OCF | 11.04 | ||
| P/B | 6.4 | ||
| P/tB | 8.15 | ||
| EV/EBITDA | 5.46 |
EPS(TTM)6.17
EY14.71%
EPS(NY)3.85
Fwd EY9.19%
FCF(TTM)3.8
FCFY9.06%
OCF(TTM)3.8
OCFY9.06%
SpS15.72
BVpS6.56
TBVpS5.14
PEG (NY)0.01
PEG (5Y)N/A
Graham Number30.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.09 |
F-Score7
WACC8.91%
ROIC/WACC7.12
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5YN/A
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.